Demographic and clinical characteristics between patients with OCD and healthy controls*
| Characteristic | Healthy controls (n = 39) | OCD (n = 51) | t or χ2 | p value |
|---|---|---|---|---|
| M/F, n | 30/9 | 40/11 | 0.029 | 0.87 |
| Education, yr | 14.10 ± 2.00 | 13.41 ± 2.19 | −1.54 | 0.13 |
| MOCI score | 4.61 ± 2.67 | 17.49 ± 5.90 | 13.85 | < 0.001 |
| Age of OCD onset, yr | — | 15.90 ± 5.80 | — | — |
| Y-BOCS score | — | 23.51 ± 7.23 | — | — |
| MADRS score | — | 16.94 ± 10.02 | — | — |
| HARS score | — | 14.45 ± 9.95 | — | — |
| Comorbid depression, n | 0 | 21 | — | — |
| Receiving SRIs, n | 0 | 51† | — | — |
| Concomitant medications | ||||
| Benzodiazepines, n | 0 | 28‡ | — | — |
| Antipsychotics, n | 0 | 4§ | — | — |
| Go/no-go task | ||||
| Successful inhibition trials, % | — | 84.51 ± 9.76 | — | — |
| Reaction time for go trials, ms | — | 300.84 ± 49.75 | — | — |
HARS = Hamilton Anxiety Rating Scale; MADRS = Montgomery–Åsberg Depression Rating Scale; MOCI = Maudsley Obsessional Compulsive Inventory; OCD = obsessive–compulsive disorder; SRI = serotonin reuptake inhibitor; Y-BOCS = Yale–Brown Obsessive Compulsive Scale.
↵* Data shown as mean ± standard deviation unless otherwise specified. All tests were 2-tailed.
↵† Escitalopram 10~40 mg/d: 16; fluoxetine 40~100 mg/d: 15; paroxetine 37.5~87.5 mg/d: 9; sertraline 100~200 mg/d: 7; fluvoxamine 200~400 mg/d: 4.
↵‡ Lorazepam-equivalent dose: 1.198 mg/d.
↵§ Quetiapine 25 mg/d, 1; quetiapine 50 mg/d, 2; aripiprazole 5 mg/d, 1.